Study guide

11.2 Severe Electrolyte Emergencies: Hyperkalemia & Hyponatremia

BCEMP Board Certified Emergency Medicine Pharmacist Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction, Triage, and Resuscitation Fundamentals

1.1 BCEMP Exam Logistics, Content Outlines & Scoring 1.2 Emergency Triage Systems (ESI) & Pre-Hospital Care Coordination 1.3 Resuscitation Pharmacology, Pharmacokinetics & Vascular Access

2 Chapter 2: Cardiac Arrest and Dysrhythmias

2.1 Adult Cardiac Arrest & ACLS Pharmacotherapy Protocols 2.2 Acute Tachyarrhythmias: Narrow- and Wide-Complex Management 2.3 Symptomatic Bradycardia & Vasoactive Chronotropic Support 2.4 Post-Cardiac Arrest Care & Targeted Temperature Management (TTM)

3 Chapter 3: Shock and Hemodynamic Resuscitation

3.1 Sepsis & Septic Shock: Surviving Sepsis Campaign 2026 Resuscitation 3.2 Cardiogenic & Obstructive Shock, Mechanical Circulatory Support & LVADs 3.3 Hypovolemic & Hemorrhagic Shock Fluid Protocols

4 Chapter 4: Airway Management and Rapid Sequence Intubation (RSI)

4.1 Rapid Sequence Intubation (RSI) Process & Pretreatment Agents 4.2 RSI Induction Agents: Pharmacology, Selection & Dosing 4.3 Neuromuscular Blocking Agents & Post-Intubation Analgosedation

5 Chapter 5: Neurocritical Care and Neurologic Emergencies

5.1 Acute Ischemic Stroke: Thrombolysis & Blood Pressure Control 5.2 Intracranial Hemorrhage & Elevated ICP Pharmacotherapy 5.3 Status Epilepticus: Tiered Emergent Anticonvulsant Therapy 5.4 Traumatic Brain Injury & Spinal Cord Emergencies

6 Chapter 6: Acute Coronary Syndromes and Acute Heart Failure

6.1 Acute Coronary Syndromes: STEMI & NSTE-ACS Pharmacotherapy 6.2 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema 6.3 Hypertensive Crises: Emergencies, Urgencies & Target Blood Pressure

7 Chapter 7: Pulmonary and Allergic Emergencies

7.1 Acute Pulmonary Embolism: Risk Stratification & Thrombolytic Therapy 7.2 Severe Asthma Exacerbation & COPD Acute Management 7.3 Anaphylaxis & Severe Allergic Reactions: Acute Epinephrine Protocols

8 Chapter 8: Clinical Toxicology: Approach to Poisoning and Common Overdoses

8.1 Approach to the Poisoned Patient: Poison Centers, Toxidromes, Decontamination & Enhanced Elimination 8.2 Acetaminophen Overdose & N-Acetylcysteine Dosing Strategies 8.3 Salicylate Toxicity & Toxic Alcohol Management (Fomepizole) 8.4 Opioid Toxicity & Sedative-Hypnotic/Alcohol Withdrawal Syndromes 8.5 Beta-Blocker & Calcium Channel Blocker Toxicity (HIET, Calcium, Glucagon)

9 Chapter 9: Toxicology: Specialized Poisonings and Antidotes

9.1 Digoxin, Tricyclic Antidepressants & Anticholinergic Toxicity 9.2 Cyanide, Carbon Monoxide & Organophosphate/Cholinergic Toxins 9.3 Snake and Spider Envenomations & Heavy Metal Chelation 9.4 Additional Antidotes: Methemoglobinemia, Isoniazid, Sulfonylureas, Valproate, Sympathomimetics & LAST

10 Chapter 10: Hemostasis, Anticoagulant Reversal, and Hematology

10.1 DOAC & Warfarin Reversal: Specific Reversal Agents & 4F-PCC 10.2 Heparin-Induced Thrombocytopenia (HIT) & Direct Thrombin Inhibitors 10.3 Sickle Cell Vaso-Occlusive Crises & Acute Chest Syndrome

11 Chapter 11: Endocrine, Electrolyte, and Metabolic Emergencies

11.1 Diabetic Ketoacidosis (DKA) & Hyperosmolar Hyperglycemic State (HHS) 11.2 Severe Electrolyte Emergencies: Hyperkalemia & Hyponatremia 11.3 Endocrine Crises: Thyroid Storm, Myxedema Coma & Acute Adrenal Crisis 11.4 Acute Kidney Injury, Dialyzability & Drug Dosing during RRT

12 Chapter 12: Infectious Diseases and Antimicrobial Stewardship

12.1 Severe Community & Hospital-Acquired Infections in the ED 12.2 Skin & Soft Tissue, STI, and Vector-Borne Emergencies 12.3 ED Antimicrobial Stewardship & Rapid Microbiologic Diagnostics

13 Chapter 13: Special Populations: Pediatrics, Trauma, and Obstetrics

13.1 Pediatric Resuscitation, Status Epilepticus & PALS Pharmacotherapy 13.2 Trauma Pharmacotherapy: Massive Transfusion, TXA, Open Fractures, Tetanus & Burns 13.3 Obstetric & Gynecologic Emergencies: Preeclampsia, Eclampsia & PPH

14 Chapter 14: Medication Safety, ED Operations, and Disaster Preparedness

14.1 ED High-Alert Medications, Error Reporting & Technology Safeguards 14.2 ED Workflow, Transitions of Care & Boarding Patient Management 14.3 Mass Casualty Incidents, CBRNE Countermeasures & Strategic Stockpiles

15 Chapter 15: Biostatistics, Study Design, and Literature Evaluation

15.1 Biostatistics & Hypothesis Testing: Power, Errors & Interpretations 15.2 Clinical Study Designs & Measures of Effect 15.3 Literature Evaluation, Clinical Guidelines & Research Conduct in the ED

16 Chapter 16: Medical Devices, Ventilation, and Medication Delivery

16.1 Mechanical Ventilation, Noninvasive Ventilation & High-Flow Oxygen: What the Pharmacist Must Know 16.2 Vascular Access, Enteral Tubes, Drains & Extravasation Management 16.3 Infusion Pumps, Patient-Owned Devices & Medication Delivery Device Counseling

17 Chapter 17: Organ-System Emergencies: GI, GU, Oncology, Neurology, ENT, Pain, and Psychiatry

17.1 Gastrointestinal & Hepatic Emergencies: GI Bleeding, Cirrhosis Complications, Pancreatitis & Vomiting 17.2 Genitourinary Emergencies: UTI & Pyelonephritis, Renal Colic, Urinary Retention, Priapism & Scrotal Infections 17.3 Oncologic, Immunotherapy & Hematologic Emergencies: Febrile Neutropenia, TLS, Hypercalcemia, irAEs, CAR-T, Hemophilia & TTP 17.4 Headache & Neuromuscular Emergencies: Migraine, Cluster, Myasthenic Crisis, Guillain-Barré & Bell's Palsy 17.5 Ophthalmologic, ENT & Dental Emergencies: Eye Injuries, Angle Closure, Angioedema, Epistaxis, Ear & Throat Infections and Dental Pain 17.6 Acute Pain Management & Procedural Sedation and Analgesia in the ED 17.7 Psychiatric Emergencies: Severe Agitation, Serotonin Syndrome, NMS, Lithium Toxicity & Psychotropic Overdose

18 Chapter 18: Special Populations, Medication Access, and Professional Practice

18.1 Pharmacogenomics, Adverse Drug Events & High-Risk Drug Interactions in Emergency Care 18.2 Special Populations: Older Adults, Extremes of Weight, Pregnancy & Lactation, and Immunocompromised Patients 18.3 Social Determinants of Health, Health Literacy & Medication Access at ED Discharge 18.4 Healthcare Regulations & Standards: FDA, REMS, Bar Coding, DEA, CMS, EMTALA, The Joint Commission, NIOSH & USP 18.5 Formulary & Inventory Management, Drug Shortages, Antidote Stocking & Clinical Decision Support 18.6 Quality Improvement, Practice Standards & Interprofessional Collaboration (Protocols, Teamwork & Debriefing)

11.2 Severe Electrolyte Emergencies: Hyperkalemia & Hyponatremia

Key Takeaways Explain This Topic AI

Hyperkalemia pharmacotherapy follows a sequenced triad: Phase 1 myocardial membrane stabilization (calcium chloride 1 g via central access or calcium gluconate 1–3 g peripheral IV), Phase 2 intracellular potassium shifting (regular insulin 5–10 units with 25–50 g dextrose, nebulized albuterol 10–20 mg), and Phase 3 potassium elimination (loop diuretics, sodium zirconium cyclosilicate, or hemodialysis).

Intravenous calcium antagonizes the cardiotoxic electrophysiological effects of hyperkalemia by raising myocardial threshold potential within 1–3 minutes without lowering serum potassium; calcium chloride provides three times more elemental calcium (270 mg vs 90 mg) than calcium gluconate but carries severe extravasation necrosis risk.

Intracellular shifting agents temporarily lower serum potassium by 0.5–1.5 mEq/L within 15–30 minutes, lasting 2–6 hours; regular insulin requires co-administration of 25–50 g of dextrose (unless glucose > 250 mg/dL) with hourly glucose monitoring for 4–6 hours to prevent delayed hypoglycemia.

Sodium zirconium cyclosilicate (Lokelma, 10 g PO TID) exchanges sodium and hydrogen for potassium throughout the intestinal tract with an onset of 1 hour, providing definitive elimination without the severe colonic necrosis risk seen with sodium polystyrene sulfonate (SPS).

Severe symptomatic hyponatremia with neurological compromise (seizures, coma, brainstem herniation) requires 3% hypertonic saline (100–150 mL IV over 10–20 min, repeatable up to 3 times) to rapidly raise sodium by 4–6 mEq/L; chronic hyponatremia correction must strictly observe the speed limit of <= 8 mEq/L per 24 hours to prevent fatal osmotic demyelination syndrome (ODS), with desmopressin (DDAVP) utilized if overcorrection occurs.

Last updated: October 2026

11.2 Severe Electrolyte Emergencies: Hyperkalemia & Hyponatremia

Note

Independent BCEMP study resource provided by ExamFinch. Content is organized around clinical emergency medicine pharmacotherapy principles and critical care electrolyte guidelines.

Hyperkalemia: Pathophysiology & Electrocardiographic Progression

Potassium is the primary intracellular cation, maintained at an intracellular concentration of 140 to 150 mEq/L versus an extracellular concentration of 3.5 to 5.0 mEq/L by the active N a + / K + Na^+/K^+ N a + / K + ATPase pump. Under the Nernst equation, this steep chemical gradient establishes the resting membrane potential (RMP) of cardiac myocytes (approximately − 90 mV -90\text{ mV} − 90 mV ).

When extracellular potassium rises, the ratio of intracellular to extracellular potassium decreases, causing the resting membrane potential to become less negative (hypopolarization). Initial hypopolarization moves the RMP closer to the threshold potential, temporarily increasing myocyte excitability. However, sustained hypopolarization progressively inactivates fast voltage-gated sodium channels, depressing phase 0 of the cardiac action potential, slowing intraventricular conduction velocity, and accelerating phase 3 repolarization. ELECTROCARDIOGRAPHIC PROGRESSION

  • ┌─────────────────────────────────────────────────────────────────────────────┐
  • │ Serum K+ ~5.5–6.5 mEq/L: Tall, peaked, narrow, symmetrical T waves │
  • │ Serum K+ ~6.5–7.5 mEq/L: PR interval prolongation, P wave flattening/loss │
  • │ Serum K+ ~7.0–8.0 mEq/L: QRS interval widening, bundle branch blocks │
  • │ Serum K+ >8.0 mEq/L: QRS merges with T wave ──> Sine Wave Pattern │
  • │ Terminal Phase: Ventricular Fibrillation, PEA, or Asystole │
  • └─────────────────────────────────────────────────────────────────────────────┘

Caution

Electrocardiographic manifestations do not correlate reliably with absolute serum potassium values. Patients may progress directly from peaked T waves to a sine wave or cardiac arrest without intermediate stages. Any confirmed serum potassium > 6.5 mEq/L >6.5\text{ mEq/L} > 6.5 mEq/L , or any hyperkalemia accompanied by ECG changes or muscle weakness, warrants immediate emergency treatment.

The Hyperkalemia Treatment Triad

The pharmacotherapeutic approach to hyperkalemia is structured into three chronological phases: membrane stabilization (immediate), intracellular translocation (minutes to hours), and total-body potassium elimination (hours). HYPERKALEMIA PHARMACOTHERAPY TRIAD

  • ┌─────────────────────────────────────────────────────────────────────────────┐
  • │ PHASE 1: STABILIZE MYOCARDIAL MEMBRANE (Onset: 1–3 min; Duration: 30–60 min)│
  • │ • Calcium Chloride 10% 1 g IV (Central line preferred; 270 mg elemental Ca)│
  • │ • Calcium Gluconate 10% 1–3 g IV (Peripheral line safe; 90 mg Ca/g) │
  • │ • NOTE: Does NOT alter serum potassium concentration! │
  • ├─────────────────────────────────────────────────────────────────────────────┤
  • │ PHASE 2: SHIFT POTASSIUM INTRACELLULARLY (Onset: 15–30 min; Duration: 2–6 h)│
  • │ • Regular Insulin 5–10 units IV + Dextrose (D50W 25–50 g) │
  • │ • Nebulized Albuterol 10–20 mg (4x asthma dose) │
  • │ • Sodium Bicarbonate 50 mEq IV (Only if severe metabolic acidemia) │
  • │ • Lowers serum potassium by 0.5–1.5 mEq/L temporarily │
  • ├─────────────────────────────────────────────────────────────────────────────┤
  • │ PHASE 3: ELIMINATE POTASSIUM FROM BODY (Onset: 1–4 h; Definitive Clearance) │
  • │ • Loop Diuretics: Furosemide 40–80 mg IV (Renal clearance) │
  • │ • GI Cation Binders: Sodium Zirconium Cyclosilicate (Lokelma) 10 g PO TID │
  • │ • Emergent Hemodialysis: Definitive extracorporeal removal (25–50 mEq/h) │
  • └─────────────────────────────────────────────────────────────────────────────┘
  • Phase 1: Myocardial Membrane Stabilization

Intravenous calcium does not lower serum potassium. Instead, extracellular calcium ions shift the threshold potential of cardiac myocytes to a less negative value (e.g., from − 75 mV -75\text{ mV} − 75 mV toward − 65 mV -65\text{ mV} − 65 mV ), restoring the normal physiological difference between the resting membrane potential and threshold potential. This restores sodium channel availability, normalizes phase 0 depolarization velocity, and prevents ventricular fibrillation.

Calcium Salt Form / Volume Elemental Calcium Administration Route Clinical Pearls

10% Calcium Chloride 1 g / 10 mL 1\text{ g} / 10\text{ mL} 1 g /10 mL ampul 270 mg 270\text{ mg} 270 mg (13.6 mEq) Central Venous Catheter (preferred) Provides 3 times more elemental calcium than gluconate. Severe tissue irritant; peripheral extravasation causes deep tissue ischemic necrosis and calcinosis cutis. Reserve peripheral use for active cardiac arrest.

10% Calcium Gluconate 1 g / 10 mL 1\text{ g} / 10\text{ mL} 1 g /10 mL ampul 90 mg 90\text{ mg} 90 mg (4.6 mEq) Peripheral Intravenous Line Non-caustic to veins; standard choice for non-arrest hyperkalemia without central access. Typical adult dose is 2 to 3 g IV over 5 to 10 minutes to equal the elemental calcium of 1 g of chloride.

Onset & Duration : Onset is 1 to 3 minutes ; duration is 30 to 60 minutes . If ECG widening persists or recurs after 5 to 10 minutes, repeat the calcium dose.

Digoxin Toxicity Controversy : Historically, calcium was withheld in digoxin toxicity due to fear of precipitating "stone heart." Contemporary clinical evidence indicates hyperkalemia-induced conduction blocks in digitalis toxicity can be treated safely with calcium, though infusion over 20 to 30 minutes and priority administration of digoxin-specific Fab fragments remains best practice.

Phase 2: Intracellular Potassium Shifting

Intravenous Regular Insulin + Dextrose :

Mechanism : Insulin stimulates the N a + / K + Na^+/K^+ N a + / K + ATPase pump on skeletal muscle and hepatocytes, driving potassium into cells independently of glucose transport.

Dosing : Regular insulin 5 to 10 units IV push co-administered with 25 to 50 grams of Dextrose (50 to 100 mL of 50% Dextrose [D50W], or 250 to 500 mL of 10% Dextrose [D10W]). In patients with baseline blood glucose > 250 mg/dL >250\text{ mg/dL} > 250 mg/dL , dextrose may be withheld with close glucose monitoring.

The 5-Unit vs 10-Unit Strategy : Observational studies and small trials suggest that 5 units of regular insulin lowers potassium nearly as much as 10 units (roughly 0.6 to 1.0 mEq/L 0.6\text{ to }1.0\text{ mEq/L} 0.6 to 1.0 mEq/L ) with substantially less hypoglycemia, especially in end-stage renal disease (ESRD), low body weight or low baseline glucose. Many protocols therefore use 5 units, or 0.1 units/kg, in these patients.

Kinetics : Onset 15 to 30 minutes ; peak 30 to 60 minutes ; duration 4 to 6 hours .

Safety Monitoring : The half-life of regular insulin is significantly prolonged in renal dysfunction (up to 4–6 hours vs 4–9 minutes in healthy kidneys). Iatrogenic hypoglycemia peaks 2 to 4 hours post-insulin administration. Serial blood glucose must be monitored every hour for at least 4 to 6 hours .

Nebulized Beta-2 Agonists (Albuterol) :

Mechanism : Stimulates beta-2 receptors, activating adenylyl cyclase, elevating intracellular cAMP, and stimulating N a + / K + Na^+/K^+ N a + / K + ATPase pumps.

Dosing : 10 to 20 mg nebulized in 4 mL normal saline over 10 to 15 minutes. This requires four to eight standard 2.5-mg nebules (4 to 8 times the standard bronchodilator dose).

Kinetics : Onset 15 to 30 minutes ; lowers potassium by 0.5 to 1.0 mEq/L ; duration 2 to 4 hours .

Synergy & Pitfalls : Highly synergistic when combined with insulin-dextrose (lowering potassium by > 1.2 to 1.5 mEq/L >1.2\text{ to }1.5\text{ mEq/L} > 1.2 to 1.5 mEq/L ). However, up to 20% to 40% of ESRD patients are non-responders due to beta-2 receptor downregulation. Avoid monotherapy; use caution in severe ischemic coronary disease or tachycardia.

Sodium Bicarbonate :

Mechanism : Exogenous bicarbonate buffers systemic acidemia, stimulating N a + / H + Na^+/H^+ N a + / H + antiport and driving intracellular K + K^+ K + shifting.

Clinical Indication : Ineffective as monotherapy for acute hyperkalemia in the absence of metabolic acidosis. Indicated strictly when hyperkalemia is accompanied by severe metabolic acidosis (pH < 7.15 to 7.20 <7.15\text{ to }7.20 < 7.15 to 7.20 , serum bicarbonate < 12 mEq/L <12\text{ mEq/L} < 12 mEq/L ) : administer 50 to 100 mEq IV push (one to two ampuls of 8.4%) or an isotonic infusion (150 mEq in 1 L D5W).

Phase 3: Potassium Excretion & Elimination

Loop Diuretics :

Furosemide 40 to 80 mg IV (or bumetanide 1 to 2 mg IV) enhances distal tubular sodium delivery and flow rate, accelerating urinary potassium excretion via the cortical collecting tubule. Only viable in patients with intact residual renal function and adequate hemodynamic volume.

Gastrointestinal Potassium Binders :

Sodium Zirconium Cyclosilicate (SZC / Lokelma) : An inorganic non-absorbed crystal lattice that captures potassium ions in exchange for sodium and hydrogen ions throughout the gastrointestinal tract. Dosing: 10 g orally three times daily for up to 48 hours, then 5 to 10 g daily for maintenance. Onset of potassium reduction occurs within 1 hour (median time to normokalemia is 2.2 hours). Crucially, SZC does not cause bowel necrosis and is well tolerated (contains ~400 mg sodium per 5 g dose; monitor for fluid retention in severe congestive heart failure).

Patiromer (Veltassa) : A non-absorbed spherical polymer that binds potassium in exchange for calcium in the distal colon. Dosing: 8.4 g orally once daily . Onset is 4 to 7 hours ; not indicated for emergent immediate reduction, but ideal for subacute hyperkalemia. Must be separated from other oral medications by at least 3 hours.

Sodium Polystyrene Sulfonate (SPS / Kayexalate) : A non-selective cation exchange resin. Administering SPS, particularly when co-formulated with 70% or 33% sorbitol, carries labeled warnings, reinforced by a 2009 FDA safety communication, about intestinal necrosis and colonic perforation , especially with sorbitol (this is a warning, not a boxed warning). Because onset is delayed (4 to 24 hours) and unpredictable, SPS has been largely replaced by SZC in modern emergency medicine formularies.

Emergent Hemodialysis :

The definitive intervention for severe, refractory hyperkalemia in patients with anuric ESRD or acute kidney injury. Hemodialysis clears 25 to 50 mEq of potassium per hour , lowering serum potassium by 1.0 to 1.5 mEq/L in the first 60 minutes.

Severe Hyponatremia: Neuro-Emergencies & Osmotic Demyelination Syndrome

Hyponatremia is defined as a serum sodium concentration < 135 mEq/L <135\text{ mEq/L} < 135 mEq/L , with severe hyponatremia defined as < 120 mEq/L <120\text{ mEq/L} < 120 mEq/L (and profound < 110 mEq/L <110\text{ mEq/L} < 110 mEq/L ). Pathophysiologic consequences are governed by the velocity of sodium decline rather than the absolute level alone.

Pathophysiology of Hyponatremic Encephalopathy

Serum sodium and its accompanying anions establish effective extracellular osmolality. When serum sodium drops, extracellular hypo-osmolality creates an osmotic pressure gradient that forces water across the blood-brain barrier through aquaporin-4 channels into astrocytic foot processes, producing cellular cerebral edema, elevated intracranial pressure, brainstem herniation, and death.

Acute Hyponatremia ( < 48 hours <48\text{ hours} < 48 hours ) : The brain has had insufficient time to adapt. Severe symptoms (seizures, coma, non-cardiogenic pulmonary edema, respiratory arrest) manifest rapidly even at sodium levels of 120 to 125 mEq/L.

Chronic Hyponatremia ( ≥ 48 hours \ge 48\text{ hours} ≥ 48 hours ) : Over 24 to 48 hours, brain astrocytes defend their cell volume through the active extrusion of intracellular electrolytes ( K + K^+ K + and C l − Cl^- C l − ) followed by organic osmolytes ( myo-inositol, taurine, glutamate, glutamine, and choline ). This regulatory volume decrease restores near-normal brain volume, rendering patients deceptively asymptomatic or only mildly confused despite profound hyponatremia ( < 115 mEq/L <115\text{ mEq/L} < 115 mEq/L ).

Osmotic Demyelination Syndrome (ODS / Central Pontine Myelinolysis)

When chronic hyponatremia is corrected too rapidly, the brain cannot synthesize and re-accumulate intracellular organic osmolytes as quickly as extracellular tonicity rises. Water is aggressively drawn out of astrocytes and oligodendrocytes into the hypertonic extracellular space. Dehydration of brain cells causes cell shrinkage, disruption of the blood-brain barrier, vascular endothelial damage, and apoptosis of myelin-producing oligodendrocytes.

Clinical Presentation of ODS : Typically manifests 2 to 7 days after rapid overcorrection. Begins with dysarthria, dysphagia, and mutism, progressing to spastic quadriparesis, pseudobulbar palsy, "locked-in syndrome" (intact cognitive function with complete motor paralysis except for vertical eye movements), coma, and death. OSMOTIC DEMYELINATION PATHOGENESIS

  • ┌─────────────────────────────────────────────────────────────────────────────┐
  • │ Chronic Hyponatremia (>=48h): Brain extrudes organic osmolytes to normalize │
  • │ cellular volume │
  • │ │ │
  • │ Rapid Sodium Correction (>8 mEq/L/d) │
  • │ │ │
  • │ ▼ │
  • │ Hypertonic Extracellular Space draws water rapidly out of brain astrocytes │
  • │ │ │
  • │ ▼ │
  • │ Acute brain cell dehydration ──> Oligodendrocyte apoptosis ──> Demyelination│
  • │ │ │
  • │ ▼ │
  • │ Locked-In Syndrome / Spastic Quadriparesis / Central Pontine Myelinolysis │
  • └─────────────────────────────────────────────────────────────────────────────┘
  • Emergent Management: 3% Hypertonic Saline Protocol

In any patient presenting with severe symptomatic hyponatremia with neurological compromise (status epilepticus, stupor, coma, respiratory depression, or signs of impending brain herniation):

First-Line Bolus Therapy : Administer 100 to 150 mL of 3% Hypertonic Saline IV over 10 to 20 minutes .

Repeat Dosing : If seizures or neurological compromise persist, repeat the 100 to 150 mL bolus up to two additional times (total of 3 boluses) at 10- to 20-minute intervals.

Therapeutic Endpoint : Target an acute increase in serum sodium of 4 to 6 mEq/L . A 4 to 6 mEq/L elevation reduces brain water content by ~10%, rapidly relieves intracranial hypertension, terminates seizures, and reverses brainstem herniation.

The Correction Speed Limit & High-Risk Thresholds

Once acute neurological symptoms are controlled, the rate of sodium correction must strictly respect physiological boundaries:

Standard Speed Limit : The 2013 US expert panel sets limits of 10 to 12 mEq/L in 24 hours (18 mEq/L in 48 hours) for average-risk chronic hyponatremia and 8 mEq/L in 24 hours for high-risk patients. Many institutions simply use ≤ 8 mEq/L \le 8\text{ mEq/L} ≤ 8 mEq/L per 24 hours for everyone , which is the safest exam answer.

High-Risk Threshold : In patients at elevated risk for ODS (advanced hepatic cirrhosis, chronic alcoholism, severe malnutrition, hypokalemia, or initial serum sodium < 105 mEq/L <105\text{ mEq/L} < 105 mEq/L ), the target is 4 to 6 mEq/L per 24 hours , with an absolute ceiling of ≤ 8 mEq/L \le 8\text{ mEq/L} ≤ 8 mEq/L per 24 hours .

Desmopressin (DDAVP) Clamp & Overcorrection Reversal Protocol

When the stimulus for antidiuretic hormone (ADH / vasopressin) release resolves—such as volume repletion in hypovolemic hyponatremia, corticosteroid administration in adrenal insufficiency, or clearance of a provoking medication in SIADH—endogenous ADH levels drop to zero. The collecting duct abruptly stops reabsorbing water, triggering massive, dilute water diuresis (aquaresis > 500 mL/h >500\text{ mL/h} > 500 mL/h ) . This causes serum sodium to surge unpredictably, exceeding the 8 mEq/L/24h speed limit and placing the patient at catastrophic risk for ODS.

Reactive Reversal of Overcorrection :

If serum sodium rises faster than 8 mEq/L in 24 hours: Immediately stop all sodium-containing fluids.

Administer Dextrose 5% in Water (D5W) IV at 3 to 5 mL/kg/h to replace ongoing free water losses.

Administer Desmopressin (DDAVP) 1 to 2 mcg IV or SQ every 6 to 8 hours to halt renal free water excretion and re-lower serum sodium back into safe boundaries.

Proactive "DDAVP Clamp" Strategy :

In patients presenting with extreme, profound chronic hyponatremia ( < 110 mEq/L <110\text{ mEq/L} < 110 mEq/L ), clinicians can proactively administer Desmopressin 1 to 2 mcg IV every 6 to 8 hours to deliberately fix urine concentrating ability. Simultaneously, 3% hypertonic saline is infused at a controlled rate (e.g., 15–30 mL/h) to raise serum sodium at a predictable rate of 4 to 6 mEq/L per 24 hours, entirely eliminating the risk of spontaneous uncontrolled aquaresis.